CYP2A6 metabolism in the development of smoking behaviors in young adults by Olfson, Emily et al.
CYP2A6 metabolism in the development of smoking behaviors in 
young adults
Emily Olfson1, Joseph Bloom2,3, Sarah Bertelsen4, John P Budde2, Naomi Breslau5, 
Andrew Brooks6, Robert Culverhouse7, Grace Chan8, Li-Shiun Chen2, David Chorlian9, 
Danielle M Dick10, Howard J Edenberg11, Sarah Hartz2, Dorothy Hatsukami12, Victor M 
Hesselbrock8, Eric O Johnson13, John R Kramer14, Samuel Kuperman14, Jacquelyn L 
Meyers9, John Nurnberger Jr15, Bernice Porjesz9, Nancy L Saccone16, Marc A Schuckit17, 
Jerry Stitzel18, Jay A Tischfield6, John P Rice2, Alison Goate4, and Laura J Bierut2
1Child Study Center and Department of Psychiatry, Yale University School of Medicine, New 
Haven, CT, USA
2Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
3Department of Anesthesiology, Washington University School of Medicine, St Louis, MO, USA
4Department of Neuroscience, Icahn School Of Medicine at Mount Sinai, New York, NY, USA
5Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA
6Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, 
Piscataway, NJ, USA
7Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
8Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT, USA
9Department of Psychiatry and Behavioral Sciences, SUNY Downstate Medical Center, Brooklyn, 
NY, USA
10Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia 
Commonwealth University, Richmond, VA, USA
11Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 
Indianapolis, IN, USA
12Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
Corresponding author: Laura Jean Bierut, M.D. Campus Box 8134, 660 South Euclid Avenue, St Louis, MO 63110 USA, 
Telephone: 314-362-3492, Fax: 314-362-4247, laura@wustl.edu. 
Disclosure/Conflict of Interest:
LJB, AG, and the spouse of NLS are listed as inventors on Issued U.S. Patent 8,080,371,“Markers for Addiction” covering the use of 
certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. JN is an investigator for Assurex and an investigator 
and consultant for Janssen. The other authors declare no conflict of interest.
Authors Contributions:
LJB, AG, JPR, DMD, HJE, VMH. JRK, SK, JN, BP, MAS, and JAT contributed to the conception and design of COGA. LJB, AG, 
JPR, EOJ, NLS, NB, DH, and JS contributed to the conception and design of COGEND. AB and JAT managed the DNA 
biorepository. JPB performed the genotyping. SB cleaned the genetic data. EO performed the statistical analyses. All authors assisted 
with analysis design and interpretation of findings. EO and LJB drafted the manuscript. All authors critically reviewed the manuscript, 
provided important intellectual feedback, and approved the manuscript.
HHS Public Access
Author manuscript
Addict Biol. Author manuscript; available in PMC 2019 January 01.
Published in final edited form as:
Addict Biol. 2018 January ; 23(1): 437–447. doi:10.1111/adb.12477.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
13Behavioral Health Epidemiology program, RTI International, Research Triangle Park, NC, USA
14Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, USA
15Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
16Department of Genetics, Washington University School of Medicine, St Louis, MO, USA
17Department of Psychiatry, University of California, San Diego Medical School, San Diego, CA, 
USA
18Institute for Behavioral Genetics, University of Colorado, Boulder, CO, USA
Abstract
CYP2A6 encodes the enzyme responsible for the majority of nicotine metabolism. Previous 
studies support that slow metabolizers smoke fewer cigarettes once nicotine dependent, but 
provide conflicting results on the role of CYP2A6 in the development of dependence. By focusing 
on the critical period of young adulthood, this study examines the relationship of CYP2A6 
variation and smoking milestones. A total of 1,209 European American young adults enrolled in 
the Collaborative Study on the Genetics of Alcoholism (COGA) were genotyped for CYP2A6 
variants to calculate a previously well-validated metric that estimates nicotine metabolism. This 
metric was not associated with the transition from never smoking to smoking initiation nor with 
the transition from initiation to daily smoking (p>0.4). But among young adults who had become 
daily smokers (n=506), decreased metabolism was associated with increased risk of nicotine 
dependence (p=0.03) (defined as Fagerström Test for Nicotine Dependence score ≥4). This finding 
was replicated in the Collaborative Genetic Study of Nicotine Dependence (COGEND) with 335 
young adult daily smokers (p=0.02). Secondary meta-analysis indicated that slow metabolizers 
had a 53% increased odds (OR=1.53, 95% CI 1.11–2.11, p=0.009) of developing nicotine 
dependence compared to normal metabolizers. Furthermore, secondary analyses examining 4 level 
response of time to first cigarette after waking (>60, 31–60, 6–30, ≤5 minutes) demonstrated a 
robust effect of the metabolism metric in COGA (p=0.03) and COGEND (p=0.004), illustrating 
the important role of this measure of dependence. These findings highlight the complex role of 
CYP2A6 variation across different developmental stages of smoking behaviors.
Keywords
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INTRODUCTION
The development of nicotine dependence requires smoking initiation, conversion from 
experimental to daily use, and finally the development of advanced smoking behaviors 
(Belsky et al., 2013; Bierut, 2011). Although the majority of adult smokers initiate smoking 
during adolescence, rates of daily smoking substantially increase during young adulthood 
(1% at ages 12–17, 12% at ages 18–25, 14% at ages 26 or more) (NSDUH, 2015). 
Furthermore, among those who report current daily smoking, the proportion of individuals 
who smoke a pack or more a day also dramatically increases with age (12% at ages 12–17, 
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23% at ages 18–25, and 33% at ages 26 or more) (NSDUH, 2015). Increasing our 
knowledge of what factors drive some young adults and not others to transition from 
initiation to daily smoking and then to advanced smoking behaviors is important for 
effectively preventing the progression toward nicotine dependence.
One genetic factor that plays an important role in the development of smoking behaviors is 
variation in the gene CYP2A6, which encodes the cytochrome P450 enzyme responsible for 
the majority of oxidation of nicotine to cotinine; this is the primary pathway of nicotine 
metabolism in humans (Hukkanen et al., 2005). The CYP2A6 locus is highly polymorphic, 
and alleles with reduced function have been associated with slower rates of nicotine 
metabolism. Common variants define multiple CYP2A6 haplotypes in individuals of 
European ancestry (Haberl et al., 2005), and the majority of inter-individual variation in the 
metabolism of nicotine to cotinine is explained by CYP2A6 genotypes in European 
Americans (Bloom et al., 2011).
The region on chromosome 19 encompassing CYP2A6 is genome-wide significantly 
associated with cigarettes per day in large meta-analyses of European ancestry adults (TAG, 
2010; Thorgeirsson et al., 2010). Among nicotine dependent adults, several studies 
demonstrate that slower metabolizers smoke fewer cigarettes per day (Benowitz, 2008; 
Malaiyandi et al., 2005). This observation is thought to reflect that smokers naturally titrate 
cigarette consumption to maintain steady nicotine levels.
Studies in youth present conflicting results regarding the effect of nicotine metabolism on 
the development of nicotine dependence and other smoking behaviors (Audrain-McGovern 
et al., 2007; Cannon et al., 2016; Chenoweth et al., 2016; Huang et al., 2005; Moolchan et 
al., 2009; O'Loughlin et al., 2004; Rubinstein et al., 2008; Rubinstein et al., 2013). Some 
studies suggest that slow nicotine metabolism is associated with an increased risk of nicotine 
dependence (Chenoweth et al., 2016; O'Loughlin et al., 2004; Rubinstein et al., 2013), 
possibly reflecting an increased sensitivity to initial nicotine exposure among youth who 
metabolize nicotine more slowly. In contrast, other studies suggest that slower metabolizers 
have a decreased risk for dependence and related symptoms (Audrain-McGovern et al., 
2007; Rubinstein et al., 2008), paralleling findings in adults regarding reduced heaviness of 
smoking among slow metabolizers.
Our goal was to investigate the ways in which variation in CYP2A6 relates to the 
development of smoking behaviors during the critical period of young adulthood in a sample 
of European Americans. A better understanding of how variation in nicotine metabolism 
contributes to the acquisition of smoking milestones will add to our fundamental knowledge 
of the developmental processes that lead to nicotine dependence and has the potential to 
identify individuals at increased susceptibility during this critical period.
MATERIALS AND METHODS
Primary Sample Description
The Collaborative Study on the Genetics of Alcoholism (COGA) is a United States multi-
center, family study that aims to identify genes that contribute to alcohol use disorders and 
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related phenotypes (Begleiter et al., 1995). Since 2005, the adolescent and young adult study 
in COGA has used a longitudinal design to examine the development of substance use 
disorders in youth from high-risk (defined as recruited through alcohol dependent probands 
with multiple affected family members) and community comparison families. Members aged 
12 to 22 were recruited from six sites across the US and interviewed approximately every 
two years with ongoing data collection. Detailed descriptions of the COGA prospective 
adolescent and young adult sample have been previously published (Chorlian et al., 2015; 
Dick et al., 2013).
Smoking Behaviors in COGA
Assessments were performed using the Semi-Structured Assessment for the Genetics of 
Alcoholism (SSAGA), which gathers detailed information on substance use with high 
reliability and validity (Bucholz et al., 1994; Bucholz et al., 1995; Hesselbrock et al., 1999). 
Smoking initiation was evaluated with the question “Have you ever smoked a full cigarette?” 
Daily smoking was defined as smoking at least 4 days per week for at least a month as done 
in previous analyses (Kapoor et al., 2012). This was assessed among individuals who had 
initiated smoking using the questions “When you were smoking regularly, how many days 
per week did you usually smoke cigarettes?” and “For how long did you smoke this many 
cigarettes at that rate?”
Among individuals who reported daily smoking (n=506), several measures of more 
advanced smoking behaviors were examined in this analysis that focused on the period of 
heaviest smoking. Time to first cigarette after waking was derived from the question “During 
this period when you were smoking the most, about how many minutes after you woke up 
did you smoke your first cigarette?” and the 4 response options: more than one hour, 31–60 
minutes, 6–30 minutes, and within 5 minutes. For the analyses, time to first cigarette was 
dichotomized into >5 minutes (n= 338, 67%) and ≤5 minutes after waking (n=168, 33%). 
Cigarettes per day was evaluated with the question “During the period of time when you 
were smoking the most, about how many cigarettes did you usually have per day?” and the 4 
response options: 10 or fewer, 11–20, 21–30, and 31 or more cigarettes. Cigarettes per day 
was dichotomized into ≤20 (n=367, 74%) and >20 cigarettes (n=131, 26%) in the analyses 
as done in previous studies (Belsky et al., 2013; Broms et al., 2006). A total Fagerström Test 
for Nicotine Dependence (FTND) score during the heaviest period of smoking was 
calculated at each interview using responses to these 2 questions as well as responses to 
questions assessing the four remaining criteria (Heatherton et al., 1991). For the analyses, 
nicotine dependence was defined as a FTND score of 4 or more (n=306, 61%), which is a 
sensitive and specific cut-off for smoking biomarkers (Huang et al., 2008) and has been used 
in previous genetic studies (Bierut et al., 2007; Saccone et al., 2009).
Given the longitudinal design of this study, an endorsement of smoking initiation or daily 
smoking at any interview at age 30 or younger was used to capture these behaviors during 
young adulthood. The highest FTND score across available interviews at age 30 or younger 
was chosen to capture the lifetime maximum, and time to first cigarette as well as cigarettes 
per day were set at these interviews.
Olfson et al. Page 4
Addict Biol. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Genotyping
Bloom et al. (2011) developed a metric based on several genetic variants in CYP2A6 to 
estimate nicotine metabolism. Cross-validation estimates that this metric predicts 
approximately 70% of the variance in metabolism of orally administered nicotine to cotinine 
in European Americans (Bloom et al., 2012). Our goal was to use this CYP2A6 metabolism 
metric to test whether CYP2A6 variation predicts cigarette smoking behaviors in young 
adulthood.
Five CYP2A6 single nucleotide polymorphisms (SNPs) (rs1801272, rs28399442, 
rs28399433, rs1137115, rs28399435) were genotyped using the LGC Genomics 
Competitive Allele-Specific PCR (KASP) (lgcgenomics.com). The CYP2A6 copy number 
variant (CNV) was genotyped with TaqMan 5’ Nuclease Assays (Life Technologies). The 
CNV assay was run in duplicate, and genotype calls were made using CopyCaller software. 
The program PEDCHECK (O'Connell and Weeks, 1998) was used to examine Mendelian 
inheritance, and only individuals with no Mendelian inconsistencies were included in the 
analyzed sample. The metabolism metric was calculated based on the genotypes of the five 
CYP2A6 SNPs and the CNV using an algorithm described in Table S1 (adapted from Bloom 
et al., 2012).
A set of 64 ancestry informative markers was genotyped as part of a 96 SNP Biorepository 
Panel by the Rutgers University Cell and DNA Repository. These markers were used in 
SNPrelate, a function in R, to assign ancestry groups. HapMap populations were included as 
reference groups. There was high concordance (98%) between self-reported and genetically 
determined ancestry among European Americans. Only individuals with a genetic ancestry 
of European American were included in the analysis because the metric was optimized for 
this population (Bloom et al., 2011).
Primary Sample Selection
The analysis was restricted to individuals who had reached young adulthood (19 years or 
older) because we were interested in transitions to daily smoking and advanced smoking 
behaviors, outcomes that often occur during this time. In the COGA adolescent and young 
adult study, 1,209 European ancestry individuals with a last interview age of 19 years or 
older were genotyped for the CYP2A6 variants, and participants for the analyses were drawn 
from this group (Figure 1). The sample used to analyze daily versus non-daily smokers 
consisted of 776 individuals who had initiated smoking (64% of all subjects). For transitions 
to advanced smoking behaviors, we focused on the sample of 506 daily smokers (65% of 
initiators, 42% of all subjects, described in Table 1).
Replication COGEND sample
The Collaborative Genetic Study of Nicotine Dependence (COGEND) is a multi-center 
case-control study designed to identify genes that contribute to nicotine dependence 
(Saccone et al., 2007). Community based recruitment enrolled participants ages 25–45 years 
old. Cases were required to be current smokers and have an FTND score of 4 or more. 
Controls were required to have smoked at least 100 cigarettes and have a lifetime maximum 
FTND score of 0 or 1. For this analysis, only subjects who self-reported as being of 
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European ancestry were examined (previous analyses using EIGENSTRAT have shown a 
high correspondence with genetic ancestry groups; Saccone et al., 2009). Genotyping of 
variants to calculate the metabolism metric in COGEND has been previously described 
(Bloom et al., 2012). We focused on the subsample of 377 COGEND young adults ages 25–
30 that overlapped with the ages of the primary COGA sample. From this group, 335 (89%) 
reported smoking every day or nearly every day for at least 2 months and were considered 
daily smokers. Replication sample characteristics of these daily smokers are described in 
Table 1.
Primary Data Analysis
Data were analyzed using the Statistical Analysis System (SAS). Logistic regression was 
used to model dichotomous outcomes of smoking initiation, daily smoking, nicotine 
dependence, time to first cigarette, and cigarettes per day. In the primary analyses in COGA 
and COGEND, the continuous metabolism metric, sex, study site, and last interview age 
were included as predictor variables. In COGA, family structure was accounted for using 
generalized estimating equations via PROC GENMOD. Results from the COGEND 
replication sample were meta-analyzed with the primary COGA results (Table 2) using a 
publically available SAS macro (http://www.hsph.harvard.edu/donna-spiegelman/software/
metaanal/). Meta-analyses results were based on fixed effect models to determine the 
evidence for association within the collected samples. In these analyses, we did not observe 
heterogeneity between the two studies based on the Q statistic (p>0.1).
Secondary Data Analyses
Secondary analyses were performed to further explore our primary findings. First, 
individuals were divided into slow and normal metabolizers using a cut-off of ≤0.85 on the 
metabolism metric as previously described (Chen et al., 2014). This cut-off captures the 
lowest quartile of metabolizers, and this dichotomous variable was used in logistic 
regression models of smoking behaviors. Second, since the majority of the COGA sample 
was recruited from families at high-risk for alcoholism, the primary analyses examining the 
continuous metabolism metric and smoking milestones were repeated with the covariate of 
lifetime DSM-IV alcoholism dependence. Third, after observing an association between the 
metabolism metric and the time to first cigarette dichotomous variable (>5 and ≤5 minutes), 
the 4 level variable of time to first cigarette after waking (>60, 31–60, 6–30, ≤5 minutes) 
was also investigated in cumulative logistic regression models. These analyses were 
performed to assess whether the continuous metabolism metric predicted response across the 
four ordinal categories.
Ethics Statement
Institutional review boards at all COGA and COGEND sites approved the study design and 
the studies were carried out in accordance with the Declaration of Helsinki. Written consent 
was received from all study participants.
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RESULTS
Participant Characteristics
Demographic, behavioral, and metabolism metric characteristics of the COGA and 
COGEND samples are presented in Table 1. The primary COGA sample of young adult 
daily smokers consisted of 506 European American individuals from 431 nuclear families 
from 310 extended families. The mean age at last interview was 24, 43% were female, and 
92% came from families at high-risk for alcoholism, with 37% meeting the criteria for 
lifetime DSM-IV alcohol dependence. Among these daily smokers, 61% were nicotine 
dependent, 33% smoked within 5 minutes after waking, and 26% smoked greater than 20 
cigarettes per day (Figure 1 and Table 1). Twenty-six percent of the young adults were slow 
metabolizers, and the distribution of the metabolism metric (Figure S1) was similar to that 
seen in other samples (Bloom et al., 2012; Chen et al., 2014).
The COGEND replication sample of young adult daily smokers consisted of 335 European 
Americans with an average age at interview of 28 and the majority were female (61%). 
Among COGEND young adult daily smokers, 50% were nicotine dependent, 24% smoked 
within 5 minutes after waking, 25% smoked greater than 20 cigarettes per day, and 31% 
were slow metabolizers (distribution in Figure S1).
CYP2A6 Metabolism Metric and Early Smoking Behaviors
The continuous CYP2A6 metabolism metric was not associated with smoking initiation 
(p=0.63) nor with the development of daily smoking (p=0.42) in the COGA young adults 
(Table 2). Of the 270 young adults who initiated smoking but did not transition to daily 
smoking, essentially all of them (98%) failed to develop any of the more advanced smoking 
behaviors, including nicotine dependence and smoking within 5 minutes after waking. This 
supports the notion that daily smoking is a prerequisite for the development of advanced 
smoking behaviors. Therefore, subsequent analyses of advanced smoking milestones 
focused on the 506 daily smokers.
CYP2A6 Metabolism Metric and Advanced Smoking Behaviors in Daily Smokers
CYP2A6 haplotypes predictive of slower metabolism were associated with an increased risk 
of nicotine dependence in both the primary COGA and replication COGEND samples of 
young adult daily smokers (Table 2, Figure 2). In multivariate models adjusting for age, sex, 
and study site, the continuous CYP2A6 metabolism metric had a significant effect in COGA 
(p =0.03) and COGEND (p=0.02), where a slow predicted metabolism was associated with 
an increased risk of nicotine dependence defined by an FTND score ≥4 (Table 2). Secondary 
analyses showed that slow metabolizers (defined by a metric of ≤0.85) had a 53% increased 
odds (OR=1.53, 95% CI 1.11–2.11, p=0.009) of developing nicotine dependence as 
compared to normal metabolizers (metric>0.85) in meta-analyses of COGA and COGEND 
studies (Table S2). Figure 2 illustrates this association by showing that a larger proportion of 
slow metabolizers in both COGA and COGEND developed nicotine dependence as 
compared to normal metabolizers.
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Consistent with the nicotine dependence results, a lower metabolism metric was associated 
with an increased risk of smoking within 5 minutes after waking (Table 2, Figure 2). The 
continuous CYP2A6 metabolism metric had a trending effect in COGA (p=0.07) and a 
significant effect in COGEND (p=0.01). In secondary meta-analysis, slow metabolizers had 
a 57% increased odds (OR=1.57, 95% CI 1.13–2.18, p=0.007) of smoking within 5 minutes 
after waking compared to normal metabolizers (Table S2). The CYP2A6 metabolism metric 
was not associated with smoking more than 20 cigarettes per day in either sample or meta-
analysis (Table 2, Figure 2). Secondary analyses examining the effect of the metabolism 
metric on smoking behaviors after controlling for DSM-IV alcohol dependence illustrates 
similar results (Table S3), supporting that the associations are not dependent on alcoholism 
status.
Robustness of effect of CYP2A6 Metabolism Metric on Time to First Cigarette after Waking
Secondary analyses using all 4 responses of time to first cigarette after waking (>60, 31–60, 
6–30, ≤5 minutes) demonstrated a more robust effect of the metabolism metric in both 
COGA (p=0.03) and COGEND (p=0.004) as compared to the dichotomous time to first 
cigarette (>5 and ≤5 minutes) used in our primary analysis (Table S4 and Table 2, 
respectively). Figure S2 illustrates that across the 4 categories, there was an increased 
proportion of slow metabolizers at shorter times to first cigarette after waking among COGA 
daily smokers. In COGEND daily smokers, we observed a similar trend, except in the 
category of 31–60 minutes that only had 19 individuals (6% of sample, Table 1). Taken 
together, these results support a possible “dosage effect” where predicted slower metabolism 
was correlated with smoking sooner after waking.
DISCUSSION
Young adulthood is a critical developmental period for the progression from initiation to 
more advanced smoking milestones (NSDUH, 2015). This study links variation in a 
genome-wide significant gene, CYP2A6, with the development of smoking behaviors in two 
independent samples of European American young adults. Using specific CYP2A6 
polymorphisms, we calculated a nicotine metabolism metric, which has been previously 
shown to account for approximately 70% of the variance in metabolism of orally 
administered nicotine to cotinine in European Americans (Bloom et al., 2012; Bloom et al., 
2011). Our primary finding is that slower nicotine metabolism is associated with an elevated 
risk of developing nicotine dependence among young adult daily smokers, adding important 
insight into the role of variation in CYP2A6 across stages of smoking development, as 
illustrated in Figure 3.
Despite having an important role in the development of nicotine dependence among daily 
smokers, variation in CYP2A6 was not associated with smoking initiation nor the 
progression to daily smoking (step 1 in Figure 3). Previous twin studies support that 
environmental influences primarily drive early adolescent nicotine use, and that the role of 
heritable factors on smoking behaviors increases throughout young adulthood (Kendler et 
al., 2008; Koopmans et al., 1999). Our results are consistent with this model by providing 
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evidence of a specific gene that impacts the transition from daily smoking to nicotine 
dependence, without influencing initiation and daily smoking.
The observation that decreased predicted nicotine metabolism is associated with increased 
risk of nicotine dependence in young adult daily smokers also builds on previous studies 
conducted in adolescents (step 2 in Figure 3). O’Loughlin et al. (2004) followed 228 non-
dependent smokers in grade 7 over approximately 30 months and found that individuals with 
less active genetic variants in CYP2A6 were more likely to develop nicotine dependence, but 
smoked fewer cigarettes per day once dependent. In a follow-up study examining 421 
adolescents who had ever smoked a cigarette, Chenoweth et al. (2016) similarly found that 
slow metabolism conferred by CYP2A6 variation was associated with increased risk of 
nicotine dependence in adolescence. Huang et al. (2005) examined variation in CYP2A6 in 
1,518 adolescents enrolled in a longitudinal study in the United Kingdom and similarly 
found that individuals with variants associated with slower metabolism were more likely to 
be current versus former smokers at age 18 compared to normal metabolizers. Rubinstein et 
al. (2013) assessed a biomarker of the rate of nicotine metabolism (the nicotine metabolite 
ratio) in 164 adolescent smokers and found that slower metabolizers showed greater 
symptoms of dependence. Our findings in two independent samples expand on these earlier 
results by demonstrating that during early young adulthood, when many advanced smoking 
behaviors develop, slow metabolizers who smoke daily continue to have a greater risk of 
lifetime dependence.
The increased susceptibility to developing nicotine dependence encountered by youth who 
are slow metabolizers compared to normal metabolizers has been hypothesized to reflect 
prolonged exposure to nicotine because of its longer half-life during initial smoking 
experiences (Chenoweth et al., 2013; Malaiyandi et al., 2005; Rubinstein et al., 2013). 
Although accumulating evidence supports this role, it is important to note that a few studies 
show the opposite effect where slow metabolism is associated with decreased risk of 
smoking behaviors in youth (Audrain-McGovern et al., 2007; Moolchan et al., 2009; 
Rubinstein et al., 2008). For example, Audrain-McGovern (2007) examined 222 adolescent 
ever-smokers of European ancestry and found that normal CYP2A6 metabolizers developed 
symptoms of dependence at a faster rate than slower CYP2A6 metabolizers. Other studies 
suggest that the increased risk of slower metabolizers for developing nicotine dependence in 
adolescence disappears by young adulthood (Chenoweth et al., 2016). Cannon et al. (2016) 
followed 296 participants across ages 16–24 and found that using a CYP2A6 diplotype 
predictive metric, intermediate metabolism compared to slow and normal was a risk factor 
for smoking frequency and nicotine dependence. By the end of the study at age 24, however, 
the individuals with predicted normal metabolism were at greatest risk for these smoking 
behaviors. Many possible explanations exist for these discrepant results. One hypothesis is 
that the effect of slower nicotine metabolism transitions rapidly from increasing risk to being 
protective (Cannon 2016; O’Loughlin 2004), and previous studies may have observed 
different developmental periods in the fast-changing early course of smoking behaviors. The 
ascertainment of subjects and baseline smoking behaviors also varies across studies, which 
may influence the power to detect associations. Furthermore, previous studies use different 
measures of smoking behaviors and nicotine dependence, and it is possible that they capture 
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different components of dependence that are differentially influenced by CYP2A6 
metabolism.
Our results suggest that time to first cigarette after waking is a critical contributor to the 
association between the CYP2A6 metabolism metric and development of nicotine 
dependence assessed by the FTND criteria among daily smokers. Little consensus exists on 
the best measure of nicotine dependence, but research supports that two items from the 
FTND score, time to first cigarette after waking and cigarettes smoked per day, are strong, 
valid, reliable predictors of quitting behaviors, which are key indicators of dependence 
(Baker et al., 2007; Borland et al., 2010; Hyland et al., 2006). Studies also suggest that these 
two measures are distinct predictors of addiction (Borland et al., 2010; Lessov et al., 2004), 
chronic obstructive pulmonary disease (Guertin et al., 2015), and lung cancer (Gu et al., 
2014), suggesting the possibility that different genetic factors may contribute to urgency to 
smoke and levels of cigarette consumption. In a sample of over 1000 young adults, 
Haberstick et al. (2007) found that time to first cigarette was the most informative measure 
of heritable factors from the FTND score. Our results complement these findings by 
illustrating that necessity to smoke measured by time to first cigarette after waking at least 
partly drives the association of the CYP2A6 metabolism metric and nicotine dependence in 
young adult daily smokers. Although the physiologic mechanism underlying this association 
remains unknown, slow metabolizer daily smokers likely have more consistent nicotine 
levels throughout the day compared to fast metabolizer daily smokers, which may contribute 
to a feeling of greater necessity to smoke in the morning when nicotine levels are low.
These findings in young adults should be considered in the context of the literature about 
adult smoking. Previous studies of adults demonstrate that once dependent, slower 
metabolizers smoke fewer cigarettes to reach target blood nicotine levels (Benowitz, 2008) 
(step 3 in Figure 3). Although we did not observe an effect of slow metabolism on risk of 
smoking more than 20 cigarettes per day among daily smokers (Table 2, Figure 2), only 26% 
of these young adults were heavy smokers, and heaviness of smoking continues to increase 
throughout adulthood (NSDUH, 2015). In the entire COGEND sample ages 25–45, a 
previous analysis demonstrated that among nicotine dependent smokers, slower metabolism 
is associated with decreased cigarette consumption (Bloom et al., 2012). It is possible that 
slow metabolism is primarily protective at high levels of cigarette consumption, which is 
most evident in older populations of adults. Overall, these findings underscore that variation 
in CYP2A6 has a variety of effects on smoking behaviors across stages of development: 
slow metabolism leads to increased risk for developing nicotine dependence in young adult 
daily smokers through time to first cigarette, but once dependent, slow metabolism is 
protective against heaviness of smoking.
Another important consideration is that the fraction of slow metabolizers in the population 
of smokers has been observed to decrease with age, suggesting that slow metabolizers are 
more likely to quit smoking (Benowitz, 2008) (step 4 in Figure 3). In the COGEND dataset, 
among current nicotine dependent smokers ages 25–30 years, we found that 36% (60/166) 
were slow metabolizers. However, among current nicotine dependent smokers over 30 years 
old, only 28% (250/883) were slow metabolizers (Chi-square, p=0.04), supporting that 
proportionally more slow metabolizers have quit by this time. Furthermore, other studies 
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directly support that slow nicotine metabolism, measured by CYP2A6 genotypes or the 
nicotine metabolite ratio, is associated with increased cessation rates in both youth 
(Chenoweth et al., 2013) and adults enrolled in clinical trials (Chen et al., 2014; Ray et al., 
2009). Taken together, these findings suggest that across development, slow metabolizers 
may quit smoking more easily. Therefore, the observation that slow metabolism is associated 
with increased risk of nicotine dependence may be most pronounced in samples of youth 
when symptoms of dependence are first developing and before cessation attempts occur.
The findings reported here have limitations. First, this study focused on individuals of 
European Ancestry because the metabolism metric was optimized for this population 
(Bloom et al., 2011). Second, the precise timing of length of transitions between smoking 
behaviors could not be examined in these analyses because the smoking questions did not 
assess age of onset. Third, the majority of the COGA participants were from families at high 
risk for alcoholism and rates of DSM-IV alcohol dependence are high in this sample, which 
may affect the generalizability of the findings. Secondary analyses that include DSM-IV 
alcohol dependence as a covariate and replication of the primary findings in a community 
based recruitment sample (COGEND), however, support the conclusion that the findings are 
not specific to a high-risk population.
In summary, using a validated CYP2A6 metabolism metric, this study demonstrates that 
slower nicotine metabolism is associated with an increased risk of nicotine dependence in 
two independent samples of young adult daily smokers. These findings add important 
knowledge about the complex role of CYP2A6 variation across different developmental 
stages of smoking behaviors.
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Figure 1. 
Primary COGA sample selection.
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Figure 2. 
Association between predicted metabolism and smoking behaviors in two studies of 
European American young adult daily smokers. Error bars reflect standard errors adjusted 
for sample size.
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Figure 3. 
A theoretical framework of the development of smoking behaviors in relation to CYP2A6 
variation. Steps 1 and 2 are supported by this paper and previous studies. Steps 3 and 4 are 
supported by previous studies (reviewed in Benowitz, 2008; Malaiyandi et al., 2005)
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Table 1
Characteristics of primary and replication samples of European American young adults
Characteristic
COGA Young Adult
European American Daily
Smokers
(n=506)
Replication: COGEND
Young Adult European
American Daily Smokers
n=335)
Sex, N (%)
  Males 288 (57%) 129 (39%)
  Females 218 (43%) 206 (61%)
Age at last interview examined, years
  Mean ± sd 24.4 ± 3.3 27.8 ± 1.7
  Range 19–30 25–30
No. of interviews examined
  Mean ± sd 4.0 ± 1.4 -
  Range 1–6 1
Family status, N (%)
  From high-risk families 464 (92%) -
  From comparison families 42 (8%) -
Lifetime DSM-IV alcohol dependence, N (%) 185 (37%) 35 (11%)
No. of extended families 310 -
No. of nuclear families (full siblings) 431 -
FTND score
  Mean ± sd 4.2 ± 2.6 3.0 ± 3.3
  Range 0–10 0–10
Nicotine dependence (FTND≥4), N (%) 306 (60%) 166 (50%)
Time to first cigarette after waking
  More than 1 hour 80 (16%) 168 (50%)
  31–60 minutes 73 (14%) 19 (6%)
  6–30 minutes 185 (37%) 67 (20%)
  Within 5 minutes 168 (33%) 81 (24%)
Cigarettes per day
  10 or fewer 182 (36%) 171 (51%)
  11–20 185 (37%) 78 (23%)
  21–30 81 (16%) 45 (13%)
  31 or more 50 (10%) 41 (12%)
Metabolism metric*
  Mean ± sd 0.86 ± 0.07 0.86 ± 0.07
  Range 0.44–0.90 0.44–0.90
Metabolism status
  Low (Metric ≤ .85) 134 (26%) 103 (31%)
  Normal (Metric > .85) 372 (74%) 232 (69%)
*
Distribution of metabolism metric in COGA and COGEND young adult daily smokers provided in Figure S1.
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